Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward for early diagnosis. The test, dubbed the Lumipulse G pTau217/ß ...

In a surprise post this afternoon, new FDA Commissioner Dr Martin Makary announced a completed pilot at the FDA of a generative AI-based system for speeding up drug review - and plans to roll out ...

FDA has a set timeline to review drugs; a norm is 10 months, called a PDUFA date. Priority Review can shorten this to six months for critical treatments. PDUFA dates are impactful, influencing ...